Chemical Compound Review:
Quinotaline propan-2-yl (2S)-7-methoxy-2...
Synonyms:
Talviraline, HBY-097, HBY097, CHEMBL430488, CHEBI:43101, ...
- Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load. Rübsamen-Waigmann, H., Huguenel, E., Paessens, A., Kleim, J.P., Wainberg, M.A., Shah, A. Lancet (1997)
- Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. Kleim, J.P., Winters, M., Dunkler, A., Suarez, J.R., Riess, G., Winkler, I., Balzarini, J., Oette, D., Merigan, T.C. J. Infect. Dis. (1999)
- Quantitative analysis of HBY 097 and its metabolites in human serum and urine by HPLC. Agarwal, V.K., Krol, G.J., Krone, V., Roberts, D. Journal of pharmaceutical and biomedical analysis. (1998)
- Crystal Structures of Clinically Relevant Lys103Asn/Tyr181Cys Double Mutant HIV-1 Reverse Transcriptase in Complexes with ATP and Non-nucleoside Inhibitor HBY 097. Das, K., Sarafianos, S.G., Clark, A.D., Boyer, P.L., Hughes, S.H., Arnold, E. J. Mol. Biol. (2007)
- Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Hsiou, Y., Das, K., Ding, J., Clark, A.D., Kleim, J.P., Rösner, M., Winkler, I., Riess, G., Hughes, S.H., Arnold, E. J. Mol. Biol. (1998)
- Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. Balzarini, J., Pelemans, H., Riess, G., Roesner, M., Winkler, I., De Clercq, E., Kleim, J.P. J. Infect. Dis. (1997)
- Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine). Balzarini, J., Pelemans, H., Riess, G., Roesner, M., Winkler, I., De Clercq, E., Kleim, J.P. Biochem. Pharmacol. (1998)
- Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. Hayashi, S., Jayesekera, D., Jayewardene, A., Shah, A., Thevanayagam, L., Aweeka, F. Journal of clinical pharmacology. (1999)
- Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro. Rübsamen-Waigmann, H., Huguenel, E., Shah, A., Paessens, A., Ruoff, H.J., von Briesen, H., Immelmann, A., Dietrich, U., Wainberg, M.A. Antiviral Res. (1999)
- Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Kleim, J.P., Bender, R., Kirsch, R., Meichsner, C., Paessens, A., Rösner, M., Rübsamen-Waigmann, H., Kaiser, R., Wichers, M., Schneweis, K.E. Antimicrob. Agents Chemother. (1995)